Eton terminates stalking horse bid for Vistogard, Xuriden; receives $800K break-up fee

Eton Pharmaceuticals, Inc.

Terminated Asset Purchase Agreement with Wellstat Debtors after losing bankruptcy auction on June 30, 2023.
Stalking horse bidder for Vistogard and Xuriden; consideration was $34M–$37M.
Received $800,000 break-up fee plus reimbursement of third-party expenses.
Eton was not the successful bidder; no assets were acquired.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Eton Pharmaceuticals, Inc. terminated Asset Purchase Agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors valued at $800,000 (effective 2023-06-30).

Action: termination
Agreement: asset purchase
Counterparty: Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M. Nesse, as Bankruptcy Trustee for the bankruptcy estates of the Debtors, and certain other affiliates of the Debtors
Value: $800,000
Effective: 2023-06-30

Exact text from the filing

(the “Company”) terminated its Asset Purchase Agreement with Wellstat Therapeutics Corporation and Wellstat Biologics Corporation (collectively, the “Debtors”), Janet M.

View on SEC.gov

Browse all material agreements →

Eton Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-023439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.